CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic Malignancy · Refractory Hematologic Malignancy · Relapsed Primary Central Nervous System Lymphoma · Refractory Primary Central Nervous System Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 152 (planned)
- Started
- Dec 28, 2017
- Main results expected
- Jul 2027
- Fully finished
- Oct 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)
Measured over: 12 months
Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs)
Measured over: 12 months
Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability data
Measured over: 12 months
Part B: Overall Response Rate (ORR) in participants with R/R PCNSL
Measured over: 18 months
Part C: ORR in participants with R/R PCNSL
Measured over: 18 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03328078 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC